ClinicalTrials.gg
Drug

Blinatumomab clinical trials

Also written Blincyto, MT103 and AMG 103.

studies test it
128
open now
56
in phase 3
23
first study started
2004

How each study uses blinatumomab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the blinatumomab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
3 Dec 2014 · BLINCYTO · BLA 125557 (FDA, Drugs@FDA)
European Union
23 Nov 2015 · Blincyto · EMEA/H/C/003731 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Blinatumomab
110
Anti-CD19 x Anti-CD3 Bispecific Monoclonal Antibody
7
Anti-CD19/Anti-CD3 Recombinant Bispecific Monoclonal Antibody MT103
7
Blinatumomab Injection
3
Blinatumomab 9ug
2

Brand

Blincyto
47

Development codes

MT103
16
AMG 103
16
MEDI-538
9

Studies by the year they started

127 studies that test it; most in 2024 (15); 1 more planned to start later

Studies that test blinatumomab, by start year
YearStudies
20041
20071
20082
20102
20111
20122
20144
20153
20165
201714
201811
20198
20207
202111
20226
20238
202415
202512
202614

Who runs them

Industry 29 · Other 99

Amgen (18) · M.D. Anderson Cancer Center (13) · National Cancer Institute (NCI) (9) · Institute of Hematology & Blood Diseases Hospital, China (9) · Amgen Research (Munich) GmbH (7) · St. Jude Children's Research Hospital (4) · Goethe University (4) · The First Affiliated Hospital of Soochow University (4)

Often tested with

Tested in the same studies.

Venetoclax (10) · Inotuzumab Ozogamicin (10) · Prednisone (6) · Cyclophosphamide (5) · Cytarabine (5) · Ponatinib (5) · Thioguanine (4) · Dexamethasone (4)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 2 phase 3 studies under way

Blinatumomab is the comparator. A study of two new drugs counts under both.

Reaching primary completion within a year · 18, 4 in phase 3

Studies that test blinatumomab, phase 3 first.

Studies

Open first, then newest update. How each study uses blinatumomab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 128

See all 128 studies that test blinatumomab →

Given beside what is tested · 21 — blinatumomab is usual care or a partner of the new treatment

Showing 20 of 21.

As the comparator · 3 — what is tested is compared with blinatumomab

Codes

What other systems call blinatumomab · ClinicalTrials.gg INT004918

  • MeSH (NLM) C510808blinatumomabConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) 4FR53SIF3ABLINATUMOMABConfirmed FDA, NLM, Wikidata
  • RxNorm 1597258Confirmed FDA, Wikidata
  • Wikidata Q410189blinatumomabConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C62528BlinatumomabOne source FDA
  • DrugBank DB09052One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.